Amplia Therapeutics with CEO Chris Burns

Double or Nothing! With Michael Frazis and Misha Saul by Michael Frazis

Sep 19, 202500:45:06Business

00:00 – Intro & welcome to Chris Burns, CEO of Amplia 02:00 – Why pancreatic cancer is so deadly & hard to diagnose 06:30 – Current treatment options: Gem/Abraxane vs FOLFIRINOX 11:20 – Side effects & challenges with che...

Related Episodes

Continue listening to more episodes from Double or Nothing! With Michael Frazis and Misha Saul.

#101: Neoclouds, semiconductors and opportunities in healthcare and software

Jul 6, 2026 - 00:22:42

00:00 Welcome back01:20 Building the portfolio gradually02:10 Semiconductor sell-off04:00 Why active mana...

#100: Market Update & Launch of ROAR

Jun 12, 2026 - 00:31:40

#99: ETF Launch - ASX:ROAR

Jun 2, 2026 - 00:36:45

ASX:ROAR Lioncrest Partners Pty Ltd (ACN 677 520 473 | CAR 001315184), an authorised representative of Fr...

#98: AI Agents, Software Collapse & the Next Tech Cycle

Feb 2, 2026 - 00:39:02

00:00 Why this AI cycle feels fundamentally different. 03:00 The shift from chatbots to fully autonomous...

#97: AI Has Entered the Takeoff Phase

Jan 12, 2026 - 00:21:11

00:00 Mike joins from Thailand and reflects on Southeast Asia’s scale, energy and contrasts. 02:00 This A...

#96: 99% of people missed it. You have 33 minutes to catch up.

Jan 5, 2026 - 00:33:17

0:00 – Intro0:45 – The AI takeoff moment: why early 2026 feels different2:20 – From ChatGPT to agents: th...

#94: Nvidia’s Red Flags, NeoCloud Bubble & the Quiet Quant Crash

Dec 28, 2025 - 00:38:36

0:00 – Intro0:42 – Nvidia earnings: strong growth but odd details2:10 – Circular Nvidia deals: inventorie...

#95 Year-End Market: AI CapEx, Nvidia, Neo-Clouds & 2026 Setup Frazis Capital Podcast

Dec 23, 2025 - 00:43:12

Why markets look “fine” but small caps are quietly crashing The brutal 50 - 60% wipeouts in quantum, nucl...